Johnson & Johnson: Neoplasms trials

The registry lists 36 Neoplasms studies with Johnson & Johnson as lead sponsor. 5 are open to participants now and 3 have results posted.

Phase 1 21Phase 2 7Phase 3 5Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of JNJ-1761981 in Participants With Solid TumorsRecruitingNCT07525141Phase 1
• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
• A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid TumorsRecruitingNCT06311578Phase 1
• A Study of JNJ-87890387 for Advanced Solid TumorsRecruitingNCT06178614Phase 1
• A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsRecruitingNCT06150157Phase 1
• A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsCompletedNCT02555878Phase 3Results posted
• A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01846611Phase 3Results posted
• A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer PainCompletedNCT01165281Phase 3Results posted
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)WithdrawnNCT05041972Phase 2
• A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid MalignanciesActive, not recruitingNCT04606381Phase 1
• A Study of JNJ-70218902 in Participants With Advanced Stage Solid TumorsCompletedNCT04397276Phase 1
• Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment OptionsApproved for marketingNCT03825484
• A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDSCompletedNCT03573310Phase 1
• A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)CompletedNCT03255070Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced CancersActive, not recruitingNCT02908906Phase 1/2
• An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisActive, not recruitingNCT02808780
• A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced CancerTerminatedNCT02671955Phase 1
• A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian CancerCompletedNCT02081495Phase 1
• A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian CancerCompletedNCT01815294Phase 1
• A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell NeoplasmsCompletedNCT01704963Phase 1
• An Observational Study of Chinese Multiple Myeloma Patients Treated With VelcadeCompletedNCT01675245
• Study of CA-18C3 in Subjects With Advanced Hematologic MalignanciesCompletedNCT01260545Phase 1
• Study of Abiraterone Acetate in Patients With Advanced Prostate CancerApproved for marketingNCT01217697
• A First in Man Study of MABp1 in Patients With Advanced CancersCompletedNCT01021072Phase 1
• A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsCompletedNCT00841191Phase 1/2
• An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer PainCompletedNCT00771199Phase 4
• A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.CompletedNCT00677001Phase 1
• A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.CompletedNCT00676910Phase 1
• A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.CompletedNCT00676299Phase 1
• PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation TherapyCompletedNCT00388336Phase 2
• An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or RadiationCompletedNCT00210587Phase 3
• A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue SarcomaCompletedNCT00102609Phase 1
• Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial CarcinomaCompletedNCT00050440Phase 2
• A Study of ET-743 (Trabectedin) in Patients With Advanced Breast CancerCompletedNCT00050427Phase 2
• A Study of Trabectedin in Patients With Advanced Ovarian CancerCompletedNCT00050414Phase 2
• Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by SurgeryCompletedNCT00036400Phase 3